

London, 22 July 2026

Dear Shareholders,

It is with great pleasure and excitement that Anastasis Biotec's management announces the upcoming 11th International Conference on **Notch and Mastermind Targeting in Cancer** (the 'Conference'), on 28-30 September, at the Grecian Park Hotel, Konnos Bay, Cyprus (www.notch2026.com).

We have lined up a diverse group of leading international scholars, researchers, clinicians and industry experts who will dive deep into the latest discoveries in Notch pathway regulation, ligand interactions, nuclear transcription, novel targetable nodes and regulatory mechanisms. Keynote speakers will share their experiences, current challenges, triumphs and future opportunities.

Notch-driven cancers account for a substantial number of cases globally. Aberrant Notch signalling pathway has drawn significant attention in the therapeutic development of cancer treatments, fostering innovative approaches leading to preclinical breakthroughs and clinical developments.

During the Conference, participants will have the opportunity to partake in hands-on workshops and discussions that will provide practical takeaways, enhance knowledge, share insights and engage in thought-provoking conversations, ensuring a dynamic and participatory experience. Connecting like-minded professionals will promote the creation of valuable relationships among scientific peers and industry representatives that will extend beyond the symposium and pave the way for future collaborations.

With this Conference, we aim to align with the pursuit of knowledge, critical thinking, and cross-border academic and industry advancement.

.... Three days filled with discovery, connection, and shared knowledge.

About Anastasis Biotec Ltd

The Company started operations in 2019 to exploit and commercialise the innovative and proprietary portfolio of its granted and filed patents.

Anastasis' unique approach lies in the way specific tumour mutations are targeted in metastatic/refractory cancers, differentiating them from other agents currently being developed for the same mutations.

The R&D pipeline enables the delivery of human therapeutic proteins into cells and sub-cellular compartments including the nucleus and across the blood-brain barrier. The data generated so far suggests a potentially transformative impact on the management of tumours with Mastermind/ Notch and p53 mutations.

Forward-Looking Statement

This document contains forward-looking statements in accordance with UK practice. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct, and the reader should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to several risks and uncertainties including, but not limited to, financing, the development of the S4, AB1, ABC products and the ANTP platform and their commercialisation by Anastasis Biotec Limited.

For more information, please contact:

Prof Agamemnon Epenetos PhD, FRCP
Chairman and CEO

agamemnon@anastasisbiotec.com

+44 7785 115 010